No abstract

1. The pharmacokinetic profile of trimethylamine (TMA) was examined in the male Wistar rat and the effects of a synthetic diet on TMA pharmacokinetics were also evaluated. 2. The concentrations of TMA and its N-oxide in blood were analysed by a sensitive headspace gas chromatographic assay. 3. The pharmacokinetics of TMA were essentially linear for intravenous (i.v.) bolus doses of 10-40 mg kg(-1). Over the range of administered i.v. doses, the concentrations of TMA in blood declined approximately monoexponentially with half-lives of 2.03-2.48 h. The Vd of TMA ranged from 3.2 to 4.39 l kg(-1) and clearance ranged from 18.78 to 23.92 ml min(-1) kg(-1). The peak concentration of TMA in blood occurred at 1 h after oral administration of a 20 mg kg(-1) dose and the bioavailability for the oral dose averaged 81%. 4. Peak concentrations of trimethylamine N-oxide (TMAO) in blood were attained at 0.73 and 1 h after i.v and oral administration of TMA (20 mg kg(-1)), respectively. 5. Feeding the male Wistar rat with a synthetic diet resulted in a twofold decrease in the clearance of TMA. Furthermore, the concentration of TMAO in blood after i.v. administration of TMA peaked at 1.25 h in rat placed on the synthetic diet as opposed to 0.75 h in rat placed on normal laboratory rat chow. The altered pharmacokinetic profile of TMA and its N-oxide suggest a diminished drug-elimination capacity in rat placed on the synthetic diet. 6. Dietary modulation of flavin-containing monooxygenase (FMO) activity may explain the effects of diet on the pharmacokinetics of TMA and its N-oxide.

The mass spectral characteristics of the N-oxides of a range of 3-substituted pyridines, and of quinoline and isoquinoline, are described. The molecular ion is the base peak in the majority of cases, provided that thermolysis is minimized when using the direct probe or gas chromatography inlets. Chromatographic and mass spectral evidence is presented which indicates that biological oxidation of the heteroaromatic nitrogen of 3-substituted pyridines is a route of metabolism in vivo and in vitro.

1. The metabolism of [2,6-14C]pyridine in vivo has been investigated in the rat, hamster, mouse, gerbil, rabbit, guinea-pig, cat and man, and the quantitative determination of the various urinary metabolites carried out by radiochromatographic analysis. 2. Unchanged pyridine and its N-methylated metabolite, N-methylpyridinium ion, were determined using a Partisil-10 SCX cation-exchange h.p.l.c. column, whereas the C- and N-oxidation products were assayed by reverse-phase chromatography, using a Partisil-10 ODS column. 3. Most of the species studied produce pyridine N-oxide, N-methylpyridinium ion, 2-pyridone, 3-hydroxypyridine and 4-pyridone as metabolites, but the proportion of the dose excreted as each of these metabolites is species-dependent.

No abstract